Standard BioTools (LAB) has kicked off Q1 2026 with revenue of about US$21.1 million and a basic EPS loss of roughly US$0.04. This sets a cautious tone around how much of that top line is flowing through to the bottom line. The company has seen quarterly revenue move between roughly US$19.6 million and US$24.8 million since Q4 2024, while basic EPS has ranged from a loss of about US$0.08 to a profit of roughly US$0.04 over the same period. This underscores how sensitive margins have been to shifts in earnings. For investors, the latest numbers keep the spotlight firmly on whether LAB can tighten costs and protect margins in a business that is still working through consistent losses.

See our full analysis for Standard BioTools.

With the headline figures on the table, the next step is to see how these results line up with the prevailing narratives about Standard BioTools, and where the numbers start to push back on those stories.

Losses remain heavy at US$14.6m for the quarter

• Net income from ongoing operations was a loss of about US$14.6 million in Q1 2026, compared with a profit of roughly US$13.9 million in Q4 2025 and losses in the US$17.7 million to US$31.7 million range across earlier 2025 quarters.
• Bears argue that structural issues in funding and integration keep profitability out of reach, and the series of quarterly losses alongside a trailing 12 month loss of about US$50.1 million supports that concern, even though recent cost actions and the SomaLogic integration have reduced operating loss and cash burn compared with earlier periods.

Trailing 12 month revenue sits at US$86.3m with modest growth

• On a trailing 12 month basis, revenue was about US$86.3 million in Q1 2026 versus US$85.3 million at Q4 2025, while the separate data set describes revenue growth over the last year averaging 0.9% annually, below the 11.3% US market benchmark cited.
• The consensus narrative sees Standard BioTools benefiting over time from mergers, partnerships, and a tilt toward higher margin consumables. However, the modest 0.9% annual revenue growth and ongoing trailing 12 month loss of roughly US$50.1 million highlight how far current performance is from the revenue expansion and margin improvement that bulls and the balanced view both link to future value.

Bulls point to cost synergies and new proteomics tools as game changers, but the latest revenue and loss run rate show how much execution still has to line up with that story before it shows up in the numbers. 🐂 Standard BioTools Bull Case

Premium 4.4x P/S despite ongoing unprofitability

• Standard BioTools is trading on a P/S of 4.4x, above both the cited US Life Sciences industry average of 3.4x and the peer average of 2.6x, while the company remained unprofitable over the last year with losses having increased at about 3.6% per year over the past five years.
• Critics highlight that paying a premium revenue multiple for a company where analysts expect no profit over the next three years is risky. The contrast between the 4.4x P/S and the ongoing trailing 12 month loss of around US$50.1 million underlines why bears focus on valuation pressure if the modest 0.9% annual revenue growth and persistent losses continue.

The stock price of about US$0.97 keeps that premium P/S in focus for cautious investors who worry that any stumble on revenue or margins could hit a multiple already above both industry and peer levels. 🐻 Standard BioTools Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Standard BioTools on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Given the mixed tone around valuation, growth and ongoing losses, it helps to check the numbers yourself and decide how comfortable you are with the risk profile here. Before drawing a firm conclusion, look closely at the company specific risk flags highlighted in the 1 important warning sign.

See What Else Is Out There

Standard BioTools is working through heavy quarterly losses, modest 0.9% annual revenue growth and a premium 4.4x P/S that keeps valuation risk front and centre.

If you want ideas where price better reflects fundamentals and profitability prospects, check out the 44 high quality undervalued stocks today and compare options against what you see in LAB.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.